14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
EKSO vs STAA: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
STAA Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 7–2 Matrix Metrics)
STAA Overall Winner
6-Pillar Tally: EKSO 1 – 5 STAA
Matrix Metrics: EKSO 2 – 7 STAA
As of Nov 20, 2026, Staar Surgical Co (STAA) is the stronger overall head-to-head candidate over Ekso Bionics Holdings, Inc. (EKSO) in the Tradestie Institutional Equity Comparison Engine, winning 7–2 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). EKSO carries a Unified Composite Score of 58.1/100 (HOLD) at $11.80 (N/M Forward P/E, -119.7% operating margin), whereas STAA carries 42.2/100 (HOLD) at $24.22 (21.4x Forward P/E, 6.8% operating margin).
Composite vs. Pillar Nuance: While EKSO currently prints a higher short-term Unified Composite Score (58.1/100 HOLD vs. STAA 42.2/100 HOLD), STAA captures the overall institutional head-to-head verdict (7–2 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (6.8% vs. -119.7% operating margin) and revenue trajectory (-12.0% vs. -38.3% YoY).
Technical & Structure Timing Caution: EKSO trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 60.4); meanwhile STAA is in a Breakdown options structure phase (RSI 47.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on EKSO vs STAA. Trailing 12-month operating profitability (EKSO -119.7% vs STAA 6.8%) and valuation multiples (EKSO N/M vs STAA 21.4x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Medical Instruments & Supplies value chain with $42.0M market capitalization and -119.7% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
STAA Moat ProfileCyclical / Execution-Driven Positioning
Medical Instruments & Supplies Operator
Competes within the Medical Instruments & Supplies value chain with $1.3B market capitalization and 6.8% operating margin.
OpEx & R&D Reinvestment66.8% of Rev ($219M)
90D Engineering Disclosures0 Published
Investor FAQ EKSO vs STAA Key Questions & Quantitative Answers
As of Nov 20, 2026, Staar Surgical Co (STAA) is the stronger overall head-to-head candidate over Ekso Bionics Holdings, Inc. (EKSO) in the Tradestie Institutional Equity Comparison Engine, winning 7–2 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). EKSO carries a Unified Composite Score of 58.1/100 (HOLD) at $11.80 (N/M Forward P/E, -119.7% operating margin), whereas STAA carries 42.2/100 (HOLD) at $24.22 (21.4x Forward P/E, 6.8% operating margin). Composite vs. Pillar Nuance: While EKSO currently prints a higher short-term Unified Composite Score (58.1/100 HOLD vs. STAA 42.2/100 HOLD), STAA captures the overall institutional head-to-head verdict (7–2 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (6.8% vs. -119.7% operating margin) and revenue trajectory (-12.0% vs. -38.3% YoY). Technical & Structure Timing Caution: EKSO trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 60.4); meanwhile STAA is in a Breakdown options structure phase (RSI 47.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
STAA leads the Growth & Scale pillar: EKSO posts -38.3% YoY revenue growth and +0.0% YoY earnings growth on $13M TTM revenue (53.5% gross margin, -119.7% operating margin), compared with STAA at -12.0% YoY revenue growth and -38.5% YoY earnings growth on $328M TTM revenue (73.6% gross margin, 6.8% operating margin). On trailing 12-month operating scale, EKSO generates $13M in USD-normalized revenue versus $328M for STAA. In operating R&D and SG&A reinvestment, EKSO deploys N/A (0 90-day corporate R&D disclosures) versus 66.8% of Rev ($219M) (0 disclosures) for STAA.
STAA screens cheaper on headline valuation multiples. EKSO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 3.3x EV/Revenue (-86.0% EBITDA margin), whereas STAA trades at 21.4x Forward P/E, N/M Trailing P/E, 0.76x PEG, and 3.5x EV/Revenue (5.4% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against EKSO (-107.6% ROE) versus STAA (0.1% ROE) capital efficiency.
In options market volatility and institutional positioning, EKSO carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (2.16β · 76% Vol realized risk). By comparison, STAA carries 179.0% implied volatility (30th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (0.64β · 61% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.